DeepSeq.AI

📍 San Francisco Bay Area, United States🗓 Founded 2019👥 4 employees💰 Last funded Dec 2025
Biotechnology Research🌐 deepseq.ai
Website LinkedIn
DeepSeq.AI is revolutionizing AI-driven drug discovery by combining novel high-throughput wet lab assays with explainable generative AI to design biologics optimized for multiple key functions. Our proprietary platform generates massive-scale protein function data and models protein "grammar," enabling the design of therapeutics optimized for conditional binding, manufacturability, efficacy, and more. Validated by paying customers, including several top global biopharma companies, and protected by a granted patent, DeepSeq.AIs technology is setting new standards in biologics discovery. Our approach has been further endorsed by investments from leading biotech accelerators, such as Merck DSS and UC Berkeley SkyDeck, as well as prestigious DARPA and NSF awards. Together, we are accelerating the future of biologics development.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in DeepSeq.AI?
DeepSeq.AI has 1 investors on record on gritt.io and 1 late-stage investors.
When did DeepSeq.AI last raise funding?
The most recent investment in DeepSeq.AI recorded on gritt.io was in December 2025.
When was DeepSeq.AI founded?
DeepSeq.AI was founded in 2019.
What industry is DeepSeq.AI in?
DeepSeq.AI operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is DeepSeq.AI based?
DeepSeq.AI is headquartered in San Francisco Bay Area, United States.